T3 Non-Small Cell Lung Cancer: Should Multimodal Therapy Be Different for Each Presentation?

Marco Chiappetta; Stefano Margaritora; Francesco Facciolo

doi:10.1016/j.athoracsur.2016.09.103

T3 Non-Small Cell Lung Cancer: Should Multimodal Therapy Be Different for Each Presentation?

Marco Chiappetta
, Stefano Margaritora
, Francesco Facciolo

IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena

Research output: Contribution to journal › Article

Abstract

na

Original language	English
Pages (from-to)	2026-2026
Number of pages	1
Journal	THE ANNALS OF THORACIC SURGERY
Volume	103
Issue number	6
DOIs	https://doi.org/10.1016/j.athoracsur.2016.09.103
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Keywords

Carcinoma
Combined Modality Therapy
Humans
Lung Neoplasms
Neoplasm Staging
Non-Small-Cell Lung

Access to Document

10.1016/j.athoracsur.2016.09.103

Cite this

@article{d689a498a3a2450484b97f26e658080c,

title = "T3 Non-Small Cell Lung Cancer: Should Multimodal Therapy Be Different for Each Presentation?",

abstract = "na",

keywords = "Carcinoma, Combined Modality Therapy, Humans, Lung Neoplasms, Neoplasm Staging, Non-Small-Cell Lung, Carcinoma, Combined Modality Therapy, Humans, Lung Neoplasms, Neoplasm Staging, Non-Small-Cell Lung",

author = "Marco Chiappetta and Stefano Margaritora and Francesco Facciolo",

year = "2017",

doi = "10.1016/j.athoracsur.2016.09.103",

language = "English",

volume = "103",

pages = "2026--2026",

journal = "THE ANNALS OF THORACIC SURGERY",

issn = "1552-6259",